According to a recent LinkedIn post from Actithera, the company has appointed Marion Masitsa M. as Director of RLT Discovery and Preclinical Sciences to lead its team in Oslo. The post highlights her extensive expertise in advancing next‑generation radioligand therapies and frames the hire as an important addition to the organization’s scientific leadership.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
For investors, this senior appointment suggests Actithera is reinforcing its research capacity in radioligand therapy, a modality attracting increasing biotech and pharma interest. Strengthening preclinical leadership in Oslo could support pipeline progression, improve the quality of early‑stage assets, and potentially enhance the company’s positioning for partnerships or future funding in the radiopharmaceuticals space.